| Stage | EHC | % of rev | MD | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.6B | 100.00% | $501M | 100.00% | EHC ×3.19 |
| Gross profit | $762M | 47.73% | $501M | 100.00% | MD +52.3pp |
| Operating income | $288M | 18.05% | $65M | 13.01% | EHC +5.0pp |
| Pre-tax income | $262M | 16.38% | $65M | 12.96% | EHC +3.4pp |
| Net income | $207M | 12.98% | $47M | 9.37% | EHC +3.6pp |
| Stage | EHC | MD | Gap · A − B |
|---|---|---|---|
| Revenue | $1.6B100.00% | $501M100.00% | EHC ×3.19 |
| Gross profit | 47.73%$762M | 100.00%$501M | MD +52.3pp |
| Operating income | 18.05%$288M | 13.01%$65M | EHC +5.0pp |
| Pre-tax income | 16.38%$262M | 12.96%$65M | EHC +3.4pp |
| Net income |
| 12.98%$207M |
| 9.37%$47M |
| EHC +3.6pp |
No disclosed counterparties: MD.
None